Ovid Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St · 03/12/2025 11:15

Ovid Therapeutics (NASDAQ:OVID) Full Year 2024 Results

Key Financial Results

  • Net loss: US$26.4m (loss narrowed by 50% from FY 2023).
  • US$0.37 loss per share (improved from US$0.74 loss in FY 2023).
earnings-and-revenue-history
NasdaqGS:OVID Earnings and Revenue History March 12th 2025

All figures shown in the chart above are for the trailing 12 month (TTM) period

Ovid Therapeutics EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 14%. Earnings per share (EPS) exceeded analyst estimates by 21%.

Looking ahead, revenue is forecast to grow 67% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are down 3.9% from a week ago.

Risk Analysis

Be aware that Ovid Therapeutics is showing 5 warning signs in our investment analysis and 3 of those make us uncomfortable...